Immuneering Corporation
IMRX
We are a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive . We are developing and seeking to commercialize an entirely new category of anti-cancer medicines, Deep Cyclic Inhibitors, which we believe have the potential to be more effective and better tolerated targeted therapies.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$67M
▲ +8.2% YoY
Op. Margin
–
ROIC
-29.21%
▲ +37.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$62M
▲ +17.4% YoY
Op. Cash Flow (TTM)
-$62M
▲ +17.6% YoY
Net Debt
-$142M
Net Cash Position
Cash & Equiv.
$145M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with IMRX
Held by ETFs
IMRX is in 6 US ETFs. The largest of them, with IMRX's weight in each:
Immuneering (IMRX) in three numbers
Questions about Immuneering
Is Immuneering a high-quality business?
Immuneering scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$142M, and its weakest is return on capital at -29.2%. The Quality tab shows every check against its target.
Does Immuneering (IMRX) pay a dividend?
No. Immuneering (IMRX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 29 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in IMRX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing IMRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.